Chronic granulocytic leukemia: Recent information on pathogenesis, diagnosis, and disease monitoring

被引:7
作者
Tefferi, A
Litzow, MR
Noel, P
Dewald, GW
机构
[1] MAYO CLIN & MAYO FDN, DIV HEMATOL & INTERNAL MED, ROCHESTER, MN 55905 USA
[2] MAYO CLIN & MAYO FDN, DIV LAB GENET, ROCHESTER, MN 55905 USA
[3] MAYO CLIN SCOTTSDALE, DIV HEMATOL ONCOL & INTERNAL MED, SCOTTSDALE, AZ USA
关键词
D O I
10.4065/72.5.445
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current evidence strongly implicates the chromosome translocation t(9;22)(q34;q11.2) as the cause of chronic granulocytic leukemia, Therefore, identification of this genetic abnormality through either cytogenetic or molecular methods has become a requirement for diagnosis, Intense investigation of the mechanism by which t(9;22) transforms normal hematopoietic progenitors into malignant cells is ongoing, Recent advances in molecular diagnostic methods have allowed refined qualitative and quantitative methods of detecting t(9;22), which are useful for monitoring response status and detecting minimal residual disease, The current understanding of the pathogenesis of chronic granulocytic leukemia and the application of new diagnostic methods are discussed.
引用
收藏
页码:445 / 452
页数:8
相关论文
共 76 条
[1]   UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE [J].
ALLAN, NC ;
RICHARDS, SM ;
SHEPHERD, PCA .
LANCET, 1995, 345 (8962) :1392-1397
[2]   DETECTION OF MINIMAL RESIDUAL DISEASE STATE IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS USING FLUORESCENCE IN-SITU HYBRIDIZATION [J].
AMIEL, A ;
YARKONI, S ;
SLAVIN, S ;
OR, R ;
LORBERBOUMGALSKI, H ;
FEJGIN, M ;
NAGLER, A .
CANCER GENETICS AND CYTOGENETICS, 1994, 76 (01) :59-64
[3]   CLINICAL DETECTION OF BCR-ABL FUSION BY INSITU HYBRIDIZATION IN CHRONIC MYELOGENOUS LEUKEMIA [J].
AMIEL, A ;
YARKONI, S ;
FEJGIN, M ;
GABER, E ;
NAGLER, A ;
MANOR, Y ;
LISHNER, M .
CANCER GENETICS AND CYTOGENETICS, 1993, 65 (01) :32-34
[4]  
BACCARANI M, 1995, LEUKEMIA, V9, P1648
[5]  
BEDI A, 1994, BLOOD, V83, P2038
[6]   BCR-ABL-MEDIATED INHIBITION OF APOPTOSIS WITH DELAY OF G2/M TRANSITION AFTER DNA-DAMAGE - A MECHANISM OF RESISTANCE TO MULTIPLE ANTICANCER AGENTS [J].
BEDI, A ;
BARBER, JP ;
BEDI, GC ;
ELDEIRY, WS ;
SIDRANSKY, D ;
VALA, MS ;
AKHTAR, AJ ;
HILTON, J ;
JONES, RJ .
BLOOD, 1995, 86 (03) :1148-1158
[7]   THE CHRONIC MYELOID LEUKEMIAS - GUIDELINES FOR DISTINGUISHING CHRONIC GRANULOCYTIC, ATYPICAL CHRONIC MYELOID, AND CHRONIC MYELOMONOCYTIC LEUKEMIA - PROPOSALS BY THE FRENCH-AMERICAN-BRITISH-COOPERATIVE-LEUKEMIA-GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, H ;
SULTAN, C ;
COX, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (04) :746-754
[8]   THE 1ST INTRON IN THE HUMAN C-ABL GENE IS AT LEAST 200 KILOBASES LONG AND IS A TARGET FOR TRANSLOCATIONS IN CHRONIC MYELOGENOUS LEUKEMIA [J].
BERNARDS, A ;
RUBIN, CM ;
WESTBROOK, CA ;
PASKIND, M ;
BALTIMORE, D .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (09) :3231-3236
[9]  
BIERNAUX C, 1995, BLOOD, V86, P3118
[10]  
BLOOMFIELD CD, 1986, BLOOD, V67, P415